Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Is Humana Inc (HUM) A Good Stock To Buy Right Now?

The elite funds run by legendary investors such as Dan Loeb and David Tepper make hundreds of millions of dollars for themselves and their investors by spending enormous resources doing research on small cap stocks that big investment banks don’t follow. Because of their pay structures, they have strong incentive to do the research necessary to beat the market. That’s why we pay close attention to what they think in small cap stocks. In this article, we will take a closer look at Humana Inc (NYSE:HUM) from the perspective of those investors.

Is Humana Inc (NYSE:HUM) undervalued? Investors who are in the know are in an optimistic mood. The number of long hedge fund bets moved up by two recently. At the end of this article we will also compare HUM to other stocks including Imperial Oil Limited (USA) (NYSEAMEX:IMO), Dollar General Corp. (NYSE:DG), and Fresenius Medical Care AG & Co. (ADR) (NYSE:FMS) to get a better sense of its popularity.

Follow Humana Inc (NYSE:HUM)
Trade (NYSE:HUM) Now!

At Insider Monkey, we’ve developed an investment strategy that has delivered market-beating returns over the past 12 months. Our strategy identifies the 100 best-performing funds of the previous quarter from among the collection of 700+ successful funds that we track in our database, which we accomplish using our returns methodology. We then study the portfolios of those 100 funds using the latest 13F data to uncover the 30 most popular mid-cap stocks (market caps of between $1 billion and $10 billion) among them to hold until the next filing period. This strategy delivered 18% gains over the past 12 months, more than doubling the 8% returns enjoyed by the S&P 500 ETFs.

health, plan, personal, money, concept, form, legal, benefit, sign, life, clinic, accident, claim, dollar, disease, banknote, remunerate, inspect, injury, medicine, currency,


Keeping this in mind, we’re going to check out the key action regarding Humana Inc (NYSE:HUM).

How have hedgies been trading Humana Inc (NYSE:HUM)?

At the end of September, 66 funds tracked by Insider Monkey held long positions in Humana, an increase of 3% from one quarter earlier. This is also the highest level achieved in terms of popularity over the last 5 quarters. With hedgies’ positions undergoing their usual ebb and flow, there exists an “upper tier” of key hedge fund managers who were upping their holdings considerably (or already accumulated large positions).
Of the funds tracked by Insider Monkey, Glenview Capital, managed by Larry Robbins, holds the number one position in Humana Inc (NYSE:HUM). Glenview Capital has a $1.6856 billion position in the stock, comprising 12.1% of its 13F portfolio. The second largest stake is held by D E Shaw holding a $432.5 million position; 0.8% of its 13F portfolio is allocated to the stock. Remaining peers that hold long positions consist of Nick Niell’s Arrowgrass Capital Partners and Ricky Sandler’s Eminence Capital.

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
This is a FREE report from Insider Monkey. Credit Card is NOT required.